Navigation Links
Over 10,000 UK Breast Cancer Patients Could Become Eligible Within,the Next Year for a Breast Cancer Therapy Showing Increased,Survival Rates, Reveals Synovate Healthcare’s European,Oncology Monitor

LONDON, April 4, 2007--Treatment data from Synovate Healthcare’s European Oncology Monitor reveals that over 10,000 breast cancer patients in the UK could become eligible for a breast cancer treatment showing lower death rates in patients. The treatment was the subject of a recent study detailed in the online edition of The Lancet (12 February 2007). Lower mortality rates were shown in patients who had switched to the aromotase inhibitor, Aromasin (exemestane), after 2-3 years of the current standard hormone drug therapy, tamoxifen. Aromasin was recently approved by the National Institute for Clinical Excellence (NICE).

Patients who could be eligible in this new indication were defined as newly diagnosed women in early stage disease who test positive for markers indicating hormone therapy as a treatment option, as well as those who have been on tamoxifen for 3 years or less. According to Synovate Healthcare’s data, 80% of drug-treated patients diagnosed in early stages are hormone responsive. Types of hormone therapies include tamoxifen and three aromatase inhibitors recently approved by the NICE. About 13% of newly diagnosed early stage breast cancer patients receive tamoxifen therapy in the UK annually.

Cancer Research UK and Globocan statistics from the World Health Organisation suggest that over 40,000 cases of breast cancer are diagnosed in the UK each year. Synovate Healthcare data shows that over 23,000 newly diagnosed patients are treated with drug therapies. Using data on the number of newly diagnosed women in early stage disease, together with the number of existing patients on tamoxifen, Synovate Healthcare estimates that over 10,000 breast cancer patients in the UK could become eligible for this new treatment within the next year.

Leah Krukowski, Head of Synovate Healthcare’s European Oncology Monitor, commented, “It is encouraging to see how many peoples&
'"/>




Page: 1 2 3

Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
3. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
4. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
5. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
6. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
7. Women Well-Informed About Breast Cancer, Yet Lacking Knowledge About Current Treatments, New Survey Finds
8. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
9. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
10. Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
11. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Post Your Comments:
(Date:7/24/2008)...Newswire/ -- There are a record 301,new medicines ... a new,report released here today during a briefin...tal illnesses have on patients, their families,an...ly 60 million American,adults. The briefing, led b... America (PhRMA), featured Emmy Award-winning acto...
(Date:7/24/2008)...to take body temperature, for home,and clinical us...-- Kidz-Med, Inc.,(subsidiary of American Scientif...s distributor of the Thermofocus(R) 5-in-1 non-con...ts of a clinical study,conducted by the Second Chi...n, Italy, which proves that the Thermofocus(R) mea...
(Date:7/23/2008)...c Therapy to Treat the Disease -, WAYNE, N.J. and.../ --,Bayer HealthCare Pharmaceuticals and Onyx Pha...that The New England Journal of Medicine published...avar(R) (sorafenib),tablets decreased the absolute...sectable hepatocellular carcinoma (HCC), or liver ...
(Date:7/23/2008)...ewswire/ -- The following was,released by the U.S....g Member Smith, and Members of the Committee.,Than...e I appeared before this Committee almost six mont...the talented and dedicated professionals,at the Ju...have come to,appreciate that much more deeply thei...
Breaking Medicine Technology:More Than 300 New Medicines Being Developed for Mental Illnesses 2More Than 300 New Medicines Being Developed for Mental Illnesses 3More Than 300 New Medicines Being Developed for Mental Illnesses 4Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Canary Foundation and American Cancer Society Award Five Postdoctoral Fellowships in Early Cancer Detection 21694 1Canary Foundation and American Cancer Society Award Five Postdoctoral Fellowships in Early Cancer Detection 21694 2Canary Foundation and American Cancer Society Award Five Postdoctoral Fellowships in Early Cancer Detection 21694 3Canary Foundation and American Cancer Society Award Five Postdoctoral Fellowships in Early Cancer Detection 21694 4Netsmarts Kevin Scalia Named Chair of the Software and Technology Vendors Association 5965 1Netsmarts Kevin Scalia Named Chair of the Software and Technology Vendors Association 5965 2Netsmarts Kevin Scalia Named Chair of the Software and Technology Vendors Association 5965 3Abnormal Sleep Patterns in Older Men Spell Trouble 21692 1Abnormal Sleep Patterns in Older Men Spell Trouble 21692 2Defeat Diabetes Foundation Announces Martial Arts Defeat Diabetes 28R 29 Community Action Project 28TM 29 21690 1Defeat Diabetes Foundation Announces Martial Arts Defeat Diabetes 28R 29 Community Action Project 28TM 29 21690 2
... Maintained for at Least 24 Weeks, According,to Re...May 15, 2007 /PRNewswire/ -- Researchers from Guy,...icine have,announced the results from the first ra...valuating botulinum toxin type A (BTX-A,BOTOX(R))...ty (IDO),in patients with symptoms of overactive b...
...S WIRE)--May 17, 2007 - Pro-Pharmaceuticals,Inc. ...carbohydrate,compounds today announced that Elieze...Development and Manufacturing will present,"Pharm...umors of,5-FU with an Admixture of a Galactomannan...developmental Biology and Medicine,(ISOBM) Confere...
Other Medicine Technology:First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder 2First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder 3First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder 4Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 2Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 3Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 4Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 5
(Date:7/25/2008)... PLEASANTON, Calif., July 25 /PRNewswire-FirstCa...ld leader in device-based mechanical,circulatory s...ing hearts,today announced that it will report it...st six months of fiscal 2008 on Thursday, July 31....uss its financial,results and operating activities...
(Date:7/25/2008)... Atlanta, GA July 24, 2008 Being overweight or o...,s health but is also a public health issue that i... journal Health Services Research reveals that t...elderly people could place a significant financial...illions of dollars across the entire current Medic...
(Date:7/25/2008)... DALLAS, July 25 /PRNewswire/ -- BeaconEquity.co...ocks making news today., Investors can view all o...ttp://BeaconEquity.com/m , Today,s Trade Alerts i...,MiddleBrook Pharmaceuticals Inc. (Nasdaq: MBRK ...aq: ADLR ), Affymetrix Inc. (Nasdaq: AFFX ) and,...
(Date:7/25/2008)...ataline is supporting the US Department of Defense...ion Golden Phoenix. Operation Golden Phoenix is a,...vent designed to assist, federal, state and local ... scenarios. Dataline is providing a vital, ad-ho...or medical use during the exercise., NORFOLK, Va....
Breaking Medicine News(10 mins):Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3
...otherapy brings about long lasting modifications i... responsible// for the mental fog and confusion in...y researchers at the University of California, Los... in the important region of the frontal cortex in ...
...r from over in Bihar with the detection of new cas...June-July immunisation drive this year//. Eight di...ered under the drive.Two new polio cases were dete...up in Arwal and Nawada districts. Patna district h...
...of daily physical exercise for their future good h...es at Glasgow University studied 545 children at 3... the children who had the recommended adult level ...three times a week, reported the online edition of...
...s, some cancer patients are experiencing unjust di...of the new legislation to protect their rights//. ...t from the end of last year has provided effective...evere illnesses like cancer, multiple sclerosis et...
Other Medicine News:Health News:Chemotherapy causes mental fog 2Health News:Injustice to cancer patients at work 2
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
Medicine Products: